Back to top

Akebia announces VOICE trial met predefined stopping criteria

Akebia (AKBA) and U.S. Renal Care announced the decision by USRC Kidney Research to stop the Vafseo Outcomes In Center Experience, or VOICE, trial ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Akebia Therapeutics, Inc. (AKBA)